We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Trinean Secures 1 Million Euro Financing

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Trinean announced to have secured a 1 million euro investment in a second closing of its 3.7 million fundraising round. The investment is done by Capricorn Health-tech Fund NV (Leuven, Belgium) which is managed by Capricorn Venture Partners NV.

Dr. Gaston Matthyssens, Trinean’s president, comments on today’s announcement: “Over the past 24 months, Trinean has proven to be able to attract substantial funding to boost its market and sales strategy, and to bring novel, state-of-the-art instruments to the market. Most recently, we have launched the Xpose®, our new micro-volume spectrophotometer for high speed quantification of nucleic acid or proteins samples”.

Dr. Frank Bulens, Partner at Capricorn Venture Partners, will join Trinean’s board of directors. “We are very pleased to enforce the existing investor syndicate of Trinean and are looking forward to assist the company in reaching its next phase of development, namely to become a successful player in the micro-volume spectroscopy market,” comments Frank Bulens, “In our view Trinean will achieve that goal based on a superior product offering supported by a seasoned management team.”

“We are delighted to welcome Capricorn Health-tech Fund to our investor syndicate,” says Philippe Stas, CEO Trinean, “This will allow Trinean to accelerate its applicationdriven expansion of the DropSense96® and Xpose® product lines and to extend our production facilities, matching the increasing demand for instruments and microfluidic solutions.”